General Biotechnology

Vertex Pharmaceuticals v. Squires is one of those rare moments where patent law, valuation math, and clinical reality collideand where the market often has to reprice faster than it can read.
Why this matters now: In the pharmaceutical industry, litiga…

Most people treat PTAB data like back-office trivia. Thats a mistake.
Heres the uncomfortable truth: for years, brand teams and their investors have talked about PTAB outcomes as if theyre surprisesrandom, political, or impossible to forecast. But if y…

Short answer: Yesmost clinicians recommend checking liver‑function tests (LFTs) before starting simvastatin (Lipitor)… https://www.Drugchatter.com/chat/30440/is-liver-function-monitoring-necessary-with-lipitor/

Dish Technologies vs. MW Media: When Just a Platform Becomes a Patent Problem
In the telecom and media world, the phrase its just infrastructure gets used a lotuntil it doesnt.
Thats the tension playing out in Dish Technologies LLC v. MW Media, LLC (se…

Dish Technologies latest legal and regulatory chess movevia its suit involving DAZN US, LLCis a reminder that the entertainment wars of today increasingly look like IP disputes, not hype cycles. And if youre an operator in media, tech, or sports rights…

Dish Technologies LLC vs. Fenix International Limited: A Reminder That Patents Dont End at the Claim LanguageThey Start There
Picture this: a patent dispute that looks, on the surface, like a routine fight over technology. But the real lesson for busin…

What flexibility side effect are you referring to with Lipitor? Lipitor (atorvastatin) is known for specific… https://www.Drugchatter.com/chat/25856/can-lipitor’s-flexibility-side-effect-lead-to-long-term-issues/

Copy-paste-ready LinkedIn post (Bloomberg-style, 5001000 words)
Patent litigation in Big Pharma is usually framed as a battle over science, strategy, and timing. But beneath the headlines is something far more mechanicaland, for generics, often far mor…

Bio betters are quietly changing the rules of the biologics gameand patent owners are feeling the heat.
Until recently, the debate around biosimilars has been framed as a straight line: innovators protect brand biologics with patents, biosimilar makers…

Stop copying molecules. Start competing on delivery.
For years, pharmas me-too instinct has been simple: find the closest known small molecule, file around the relevant claims, and let time and litigation do the rest. But the next wave of competitive a…